Abstract: The invention discloses using secreted splicing variant of mammal Klotho (s-KL) as an agent for the prevention and/or treatment of cognitive and/or behaviour impairments. It also refers to gene constructs and expression vectors useful in gene therapy for the delivery of said s-KL variant to the central nervous system of a mammal, in particular a rodent or a human. Pharmaceutical compositions comprising either the protein s-KL or any gene construct for expressing the protein in the CNS are also disclosed.
Type:
Grant
Filed:
November 21, 2016
Date of Patent:
July 16, 2024
Assignees:
Universitat Autònoma De Barcelona, Fundació Institució Català de Recerca i Estudis Avançats
Inventors:
Miguel Chillon Rodriguez, Anna Masso Chacon, Assumpció Bosch Merino
Abstract: An extrusion-based additive manufacturing process including the step of selectively depositing a molten thermoplastic material (P) on a film or sheet made from or containing a polymer blend obtained by melt blending a mixture made from or containing: (A) 60% to 98.8% by weight of a polyolefin; (B) 0.1% to 30% by weight of a compatibilizer; (C) 0.05% to 20% by weight of an amino resin; and (D) 0% to 5% by weight of an additive, wherein the amounts of (A), (B), (C) and (D) are based on the total weight of (A)+(B)+(C)+(D).
Inventors:
Carl Gunther Schirmeister, Erik Hans Licht, Karsten Schmitz, Yannic Kessler, Klaus Klemm, Jürgen Rohrmann, Dieter Langenfelder, Mikhail Dureev, Rolf Muelhaupt, Mirco Müller, Steer Peter, Kolano Benjamin
Abstract: A method and a system for detecting microwave signals which carry information of the functional dynamics of biological particles are provided.
Type:
Application
Filed:
February 15, 2022
Publication date:
July 11, 2024
Applicant:
UNIVERSITAT POLITECNICA DE CATALUNYA
Inventors:
Marc JOFRE CRUANYES, Lluís JOFRE CRUANYES, Luis JOFRE ROCA, César Augusto PALACIOS ARIAS, Jordi ROMEU ROBERT, Juan Manuel O'CALLAGHAN CASTELLÀ
Abstract: The present invention relates to a medical system (20) for measuring visual evoked potentials (VEP) of a person, comprising a display (2) for displaying images to be observed by the person with a single eye, and an image generating module (1), the image generating module (1) being configured to cause the display (2) to display a sequence of images comprising a first image and a second image. The medical system (20) further comprises: a plurality of electrodes (3) configured to be attached to the scalp of the person and to detect EEG signals indicative of electrical activity in the brain of the person in response to observing said sequence of images displayed by the display (2), an EEG recording module (4) connected to said plurality of electrodes (3), the EEG recording module (4) being configured to record said EEG signals, and an analyzing module (8), the analyzing module (8) being configured to derive from said EEG signals recorded by the EEG recording module (4) at least one visual evoked potential (VEP).
Abstract: The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.
Type:
Application
Filed:
August 5, 2021
Publication date:
July 11, 2024
Applicants:
Basilea Pharmaceutica International AG, Allschwil, UNIVERSITÄT ZÜRICH
Inventors:
Daniel OBRECHT, Anatol LUTHER, Grégory UPERT, Nicolas DESJONQUERES, Emile BRABET, Peter ZBINDEN, Oliver ZERBE, Kerstin MÖHLE
Abstract: The present invention relates to a medical device (1) for determining an oxygen saturation in a tissue of a subject, comprising: a sensor (2) comprising a flexible textile (10) comprising a plurality of first optical fibers (11) and a plurality of second optical fibers (12), wherein the first optical and second optical fibers (11, 12) each comprise a first end (11a, 12a) and a second end (11b, 12b), wherein the sensor (2) further comprises a first light generating unit (3) configured to generate and couple light of a first wavelength into the first ends (11a) of the first optical fibers (11) and to generate and couple light of a second wavelength into the second ends (12a) of the first optical fibers (11), the first wavelength being different from the second wavelength, wherein the respective first optical fiber (11) is configured to emit light via a light emitting section (21) of the respective first optical fiber (11) to irradiate tissue of the subject, the light emitting section (21) being arranged between
Type:
Application
Filed:
May 23, 2022
Publication date:
July 11, 2024
Applicants:
UNIVERSITÄT BERN, EMPA
Inventors:
Ursula WOLF, Oliver DA SILVA-KRESS, Tarcisi CANTIENI, Luciano BOESEL, René ROSSI, Nazanin ANSARI, Markus MICHLER
Abstract: The application describes a T-cell expressing a chimeric antigen receptor (‘CAR T-cell’) containing superparamagnetic iron-based particles (‘loaded CAR T-cell’) for use in treating a tumor. Said loaded CAR T-cell exhibits a reduced cytokine release upon binding to a cell of the tumor expressing an antigen being recognized by the CAR of the CAR T-cell, compared to a CAR T-cell not containing superparamagnetic iron-based particles (‘unloaded CAR T-cell’) under the same conditions. Furthermore, an in vitro method of generating a CAR T-cell containing superparamagnetic iron-based particles is described, whereby such loaded CAR T-cells are generated.
Abstract: A novel ultra-thin neural implant (1) is provided that is based on a cellulose thin film (4) featuring an array (2) of electrodes (3). Due to the use of cellulose as the base material, the implant (1) can be safely handled during a micro-surgery, despite its high softness and conformability. Such an implant (1) may be useful in numerous applications ranging from electrical stimulation in neural prostheses, electro-stimulated regeneration of neural tissue to accurate recording of nerve signals. The robustness of the implant (1) results from a woven fabric (5) that is integrated in the cellulose carrier thin film (4). Several approaches for enhancing the tissue compatibility of the implant (1) are also provided.
Type:
Application
Filed:
May 6, 2022
Publication date:
July 11, 2024
Applicant:
Universität Basel Vizerektorat Forschung
Abstract: The present invention relates to agents for use in the treatment of glioma, in particular astrocytoma WHO II° and III°, as well as IV° (glioblastoma), in a subject.
Type:
Grant
Filed:
January 5, 2022
Date of Patent:
July 9, 2024
Assignee:
Universität Heidelberg
Inventors:
Matthias Osswald, Wolfgang Wick, Frank Winkler, Erik Jung, Jonas Blaes
Abstract: A pyrophosphate-free mixture with fire retardancy, including a mixture of non-polymer organic components, wherein at least a first compound of the mixture acts as a hydrogen-bridge donor and at least a second compound of the mixture acts as a hydrogen-bridge acceptor. The disclosure also relates to a method for preparing the fire-retardant mixture and to the use thereof as a fire retardant in extinguishing forest fires.
Type:
Grant
Filed:
December 29, 2020
Date of Patent:
July 9, 2024
Assignees:
PRIMALCHIT SOLUTIONS, S.L., CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, UNIVERSITAT POLITÈCNICA DE VALÉNCIA
Inventors:
Francisco Antonio Alandí Escrig, Abdessamad Grirrane Tayari, Hermenegildo García Gómez, Juan Llobell Lleó, Regina García Mondria
Abstract: The invention relates to a gas bearing for contactlessly bearing a rotatable element (50). The gas bearing comprises: a housing (100) having an opening for receiving the rotatable element; and at least two sliding films (200), which are arranged on an interior (110) of the opening without overlap and which each have a first end portion (210) and a second end portion (220) for support on the housing (100). The sliding films (200) are designed to radially support the rotatable element relative to the housing (100) only by means of the first and second end portions (210, 220), the second end portion (220) providing frictional contact with the interior (110) and the first end portion (210) being fastened to the housing.
Type:
Grant
Filed:
December 17, 2019
Date of Patent:
July 9, 2024
Assignee:
Technische Universität Darmstadt
Inventors:
Bernhard Schweizer, Marcel Bauer, Marcel Mahner, Markus Rieken, Pascal Zeise
Abstract: A method for determining a focal length of a particle in a medium, wherein the method comprises: providing a sample; emitting a coherent light beam to irradiate the sample, wherein a first part of the light beam is scattered by the particle; recording an interference image; computing for a set of positions an electric field from the interference image; generating a representation comprising, for each of said positions, an intensity value of the coherent light beam calculated from the computed electric field; finding two positions, a first of which lies in the sample, a second of which lies in the beam direction behind or in front of said first position; and determining the focal length from the two found positions.
Type:
Grant
Filed:
April 29, 2021
Date of Patent:
July 9, 2024
Assignee:
Universität für Bodenkultur Wien
Inventors:
Petrus Dominicus Joannes Van Oostrum, Erik Olof Reimhult
Abstract: The invention relates to an optical waveguide with two or more light-guiding cores (1a-1e) extending continuously along the longitudinal extension of the optical waveguide, parallel to one another and spaced apart from one another, from one end of the optical waveguide to the other, and with a first cladding (2) enclosing the cores (1a-1e). It is an object of the invention to provide a multicore optical waveguide for high-power operation with reduced system complexity compared to the prior art.
Type:
Grant
Filed:
June 4, 2020
Date of Patent:
July 9, 2024
Assignees:
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., Friedrich-Schiller-Universität Jena
Inventors:
César Jáuregui Misas, Jens Limpert, Andreas Tünnermann
Abstract: The present invention relates to a method of diagnosing eczema and/or psoriasis, wherein said method differentiates between eczema and psoriasis, and comprises determining the expression of at least two markers in a sample taken from an individual, wherein said at least two markers are selected from CCL27, NOS2, IL36G, KLK13, SOST, NPTX1, PLA2G4D, GDA, IL36A, TGM1, CLEC4G, IL13, TCN1, TMPRSS11D and RHCG, provided that said at least two markers consist of or comprise (a) CCL27 and NOS2; (b) CCL27 and KLK13; (c) IL36G and KLK13; (d) CCL27 and IL36G; (e) NOS2 and IL36G; (f) NOS2 and KLK13; (g) SOST; or (h) NPTX1; and assessing on the basis of the expression of said at least two markers whether the individual is afflicted with eczema and/or psoriasis.
Type:
Grant
Filed:
May 31, 2019
Date of Patent:
July 9, 2024
Assignees:
HELMHOLTZ ZENTRUM MÜNCHEN— DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH), KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN
Abstract: Kinase-targeted covalent inhibitors are usually irreversibly targeting noncatalytic cysteines in the ATP-binding site. These compounds are designed by directly introducing an electrophile on a reversible-inhibitor scaffold. Our invention relates to novel triazine compounds, containing chemical reactive groups (warheads), targeting a solvent exposed cysteine at >10 ? from the core reversible inhibitor. A variety of novel linkers have been designed and used to link the warhead with the reversible scaffold. We disclose a novel chemical space for drug-like covalent modifiers of phosphoinositide 3-kinase alpha (PI3K?), an enzyme frequently altered in human malignancies. The invention relates to novel covalent inhibitors showing higher in vitro affinity, cellular potency and improved metabolic stability (rat liver microsomes).
Abstract: The invention relates to a hydroxycarboxylic acid of the formula CH3(CH2)8 CHOH—(CH2)—CO2H or a pharmaceutically acceptable salt thereof, for use as a medicament, particularly for use in the treatment or prevention, including prevention of recurrence, of cancer, for example colorectal cancer. The invention further relates to a combination medicament for use in the treatment or the prevention of recurrence of cancer comprising a hydroxycarboxylic acid as specified herein, and another antineoplastic treatment. Further aspects of the invention relate to a method of measuring the presence of a hydroxydicarboxylic acid of the formula HO2C(CH2)7 CH2CHOH—(CH2)—CO2H, or CH3(CH2)10COOH to predict or to monitor the clinical outcome of a cancer patient, and/or to predict or monitor the response to an antineoplastic therapy or treatment with live bacteria.
Type:
Application
Filed:
April 24, 2022
Publication date:
July 4, 2024
Applicant:
UNIVERSITÄT ZÜRICH
Inventors:
Michael SCHARL, Ana MONTALBAN-ARQUES, Egle KATKEVICIUTE, Yasser MORSY
Abstract: It is provided a storage medium for storing hydrogen chloride (HCl) comprising at least one ionic compound of the general formulae (I) Wherein R1, R2, R3 being independent from each other an alkyl moiety selected from the group of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and sec-butyl, preferably methyl, ethyl, n-propyl; Wherein at least one of the moieties R1, R2, R3 differs from each of the others moieties R1, R2, R3; Wherein a, b, c are independently from each other 0, 1, 2 or 3, wherein the sum of a+b+c always has to be 4; Wherein n>=1, preferably n=1-6, more preferably n=1, 2, 3, 4, with a viscosity in a range between 5 and 50 mPas, preferably between 10 and 20 mPas (25° C., 1000 hPa).
Type:
Application
Filed:
August 11, 2022
Publication date:
July 4, 2024
Applicant:
FREIE UNIVERSITÄT BERLIN
Inventors:
Sebastian HASENSTAB-RIEDEL, Patrick VOßNACKER
Abstract: An automated system for inspecting Petri dishes in which multiple C. elegans nematodes coexist, such that precise mobility characteristics of each individual C. elegans nematode can be extracted. The Petri dish to be monitored is moved in a controlled manner along the X, Y, and Z axes with respect to at least one movable camera that captures a high-resolution sequence of images for each C. elegans nematode, and at least one fixed camera captures a low-resolution sequence of global images that allow the entire Petri dish to be framed. The movable camera is mounted on a movable head in order to move along the Z axis, enabling focusing, and the fixed camera is mounted on a movable trolley, together with the Petri dish, in order to move along the X and Y axes.
Type:
Application
Filed:
April 27, 2022
Publication date:
June 27, 2024
Applicant:
UNIVERSITAT POLITÈCNICA DE VALÈNCIA
Inventors:
Antonio José SÁNCHEZ SALMERÓN, Joan Carles PUCHALT RODRÍGUEZ, José Félix GONZÁLEZ ROJO, Carlos RICOLFE VIALA
Abstract: Our invention relates to novel triazine compounds, containing chemical reactive groups (warheads) and behaving as reversible and irreversible covalent inhibitors. Linkers have been introduced to target a solvent exposed, distal cysteine at >10 ? from the core reversible inhibitor. Different exit vectors have been investigated to modulate inhibitor intrinsic reactivity and efficiency in covalent bond formation. We disclose novel, optimized covalent modifiers of phosphoinositide 3-kinase alpha (PI3K?), an enzyme frequently altered in human malignancies. The compounds of the invention could be exploited as therapeutic agents and chemical probes useful for the investigation of the role of PI3K isoforms in cancer and metabolism, and for treatment of PI3K?-driven cancers and malformations.